MIRA INFORM REPORT

 

Report No. :

330052

Report Date :

14.07.2015

 

IDENTIFICATION DETAILS

 

Correct Name :

FARMACEUTICA PARAGUAYA S.A.

 

 

Registered Office :

Avda. Aviadores del Chaco 2462 entre Santa Teresa y San Blas, Asuncion

 

 

Country :

Paraguay

 

 

Year of Establishment :

1975

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Processing and Marketing of Medical Specialties for Human Use.

 

 

No. of Employees :

500 Employees

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 


 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Paraguay

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

PARAGUAY - ECONOMIC OVERVIEW

 

Landlocked Paraguay has a market economy distinguished by a large informal sector, featuring re-export of imported consumer goods to neighboring countries, as well as the activities of thousands of microenterprises and urban street vendors. A large percentage of the population, especially in rural areas, derives its living from agricultural activity, often on a subsistence basis. Because of the importance of the informal sector, accurate economic measures are difficult to obtain. On a per capita basis, real income has stagnated at 1980 levels. The economy grew rapidly between 2003 and 2008 as growing world demand for commodities combined with high prices and favorable weather to support Paraguay's commodity-based export expansion. Paraguay is the sixth largest soy producer in the world. Drought hit in 2008, reducing agricultural exports and slowing the economy even before the onset of the global recession. The economy fell 3.8% in 2009, as lower world demand and commodity prices caused exports to contract. The government reacted by introducing fiscal and monetary stimulus packages. Growth resumed at a 13% level in 2010, the highest in South America, but slowed in 2011-13 as the stimulus subsided and severe drought and outbreaks of foot-and-mouth disease led to a drop in beef and other agricultural exports. The economy took another leap in 2014, largely due to strong export growth. Political uncertainty, corruption, limited progress on structural reform, and deficient infrastructure are the main obstacles to long-term growth.

 

Source : CIA

 


Registered Name

 

FARMACEUTICA PARAGUAYA S.A.

*FAPASA*

R.U.C. Nº 80006276-0

 

 

Summary

 

BEGINNER OF ACTIVITIES, INCORPORATED IN 1975. NO FINANCIAL DATA PROVIDED ONLY TO BANKS AND TAX COMPTROLLERS. NO NEGATIVE REGISTERED. APT FOR CURRENT CREDITS.

 

 

Operations

 

PROCESSING AND MARKETING OF MEDICAL SPECIALTIES FOR HUMAN USE.

 

 

Legal Structure

 

LEGAL FORM:                         PUBLIC LIMITED COMPANY
CREATED:                               1975
REGISTERED RPC:                  1975
DURATION:                              UNLIMITED
END OF FISCAL YEAR:            31.12

 

 

Contact

 

Accountant: Liliana Garcete

Legal and administrative address:
Avda. Aviadores del Chaco 2462 entre Santa Teresa y San Blas, Asuncion, Republic of Paraguay.

Phone: 00595-21 614450/4
E.Mail: liliana.garcete@fapasa.com.py
Web:    www.fapasa.com.py

 

Partners

 

LEGAL REPRESENTATIVE:   OSVALDO FORMENTO

Using signature: It is in charge of before mentioned.

 

 

History

 

Reference activities were initiated directly by the company, which is engaged in the development, production and marketing of medicines for human use.

In 2004, health authorities in Argentina, Uruguay and Paraguay holder awarded to GMP compliance certification for the marketing of products in MERCOSUR. It exports to Brazil and has won approval from the health authorities of Pakistan, Colombia, Mexico, so the recertification cone with scope to Argentina and Paraguay, for 5 years.

The company has licenses for the following international laboratories:
CELGENE (EE.UU-SUIZA)
ALPHEX PHARMA (SUIZA)
TOLMAR (USA)
MEIJI SEIKA (JAPON)
DEBIOPHARM (SUIZA)
LABORATORIOS PHOENIX (ARGENTINA)

 

 

Economic-Financial Position

 

Attended by the Accountant Garcete Liliana, who showed that by directives primarily responsible for the company did not provide reports, let alone of financial character.

 

 

Assets

 

A society is given possession of the property in which it operates its head office and production plant, which by their characteristics have a significant value of realization.

It also has several vehicles of different models.

 

 

Evolution and Results

 

Is dedicated to the development of the abovementioned activities.


Imports from Brazil, Argentina, India, Switzerland and exports to Brazil, Argentina, Colombia, Mexico and Pakistan.

CELGENE (SWITZERLAND)
ALPEX PHARMA (SWITZERLAND)
DEBIOPHARM (SWITZERLAND)

* 500 EMPLOYEES

 

 

Branches

 

Plant of production:

Waldino Ramon Lovera y del Carmen, Fernando de la Mora, Republic of Paraguay.

Branchs:

Gral. Eugenio Garay nº 112 esq. Juan A. Roa, Cnel. Oviedo, Paraguay.

- Calle UV Monday, Ciudad del Este, Paraguay.

- Gral. Cabañas 235, Encarnacion, Paraguay.

 

 

Payment Record and Credit Risk

 

BANCO ATLAS
BANCO CONTINENTAL
BANCO REGIONAL

Centralhouse

INSURANCE:
----------
MAPFRE S.A.

 

 

Concept

 

It is commercially related to companies of this one and other places, good part of which offer its credit support without making until the moment objections on the modes of payment that it sustains.

* FULFILLMENT: NOT OBJECTED.

 

 


Final Opinion

 

The lack of negative antecedents makes viable the credit relation with the company, by current credits and additional guarantees.

* APT FOR CURRENT CREDITS.


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.47

UK Pound

1

Rs.98.47

Euro

1

Rs.70.69

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIT

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.